4.3 Article

The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects

Journal

BRAIN TOPOGRAPHY
Volume 29, Issue 2, Pages 296-307

Publisher

SPRINGER
DOI: 10.1007/s10548-015-0455-1

Keywords

OPLS; Age correction; Alzheimer's disease; Mild cognitive impairment; MRI; Early diagnosis; Diagnostic misclassification

Funding

  1. Karolinska Institutet
  2. Axel Fondation
  3. Signe Lagermans Donation Fondation
  4. Academy of Finland
  5. EVO Kuopio University Hospital
  6. University of Eastern Finland, UEFBRAIN
  7. InnoMed, (Innovative Medicines in Europe) an Integrated Project - European Union [FP6-2004-LIFESCIHEALTH-5]
  8. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  9. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  10. National Institute on Aging
  11. National Institute of Biomedical Imaging and Bioengineering
  12. Alzheimer's Association
  13. Alzheimer's Drug Discovery Foundation
  14. Araclon Biotech
  15. BioClinica, Inc.
  16. Biogen Idec Inc.
  17. Bristol-Myers Squibb Company
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. EuroImmun
  22. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd.
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC
  27. Johnson & Johnson Pharmaceutical Research & Development LLC
  28. Medpace, Inc.
  29. Merck Co., Inc.
  30. Meso Scale Diagnostics, LLC.
  31. NeuroRx Research
  32. Neurotrack Technologies
  33. Novartis Pharmaceuticals Corporation
  34. Pfizer Inc.
  35. Piramal Imaging
  36. Servier
  37. Synarc Inc.
  38. Takeda Pharmaceutical Company
  39. Canadian Institutes of Rev Health Research
  40. Northern California Institute for Research and Education
  41. National Institute for Health Research [NF-SI-0512-10053] Funding Source: researchfish

Ask authors/readers for more resources

The similarity of atrophy patterns in Alzheimer's disease (AD) and in normal aging suggests age as a confounding factor in multivariate models that use structural magnetic resonance imaging (MRI) data. To study the effect and compare different age correction approaches on AD diagnosis and prediction of mild cognitive impairment (MCI) progression as well as investigate the characteristics of correctly and incorrectly classified subjects. Data from two multi-center cohorts were included in the study [AD = 297, MCI = 445, controls (CTL) = 340]. 34 cortical thickness and 21 subcortical volumetric measures were extracted from MRI. The age correction approaches involved: using age as a covariate to MRI-derived measures and linear detrending of age-related changes based on CTL measures. Orthogonal projections to latent structures was used to discriminate between AD and CTL subjects, and to predict MCI progression to AD, up to 36-months follow-up. Both age correction approaches improved models' quality in terms of goodness of fit and goodness of prediction, as well as classification and prediction accuracies. The observed age associations in classification and prediction results were effectively eliminated after age correction. A detailed analysis of correctly and incorrectly classified subjects highlighted age associations in other factors: ApoE genotype, global cognitive impairment and gender. The two methods for age correction gave similar results and show that age can partially masks the influence of other aspects such as cognitive impairment, ApoE-e4 genotype and gender. Age-related brain atrophy may have a more important association with these factors than previously believed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available